ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Exscientia, a UK-based drug discovery firm, will work with the University of Texas MD Anderson Cancer Center on discovery and development of small-molecule oncology therapies. The partners will deploy Exscientia’s artificial intelligence–based discovery platform to identify cell-intrinsic small molecules that act on cancer targets. Candidates will be further developed by MD Anderson with the goal of moving programs into clinical trials at the cancer center.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter